Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
2LB Stock Chart & Stats
€3.32
-€0.05(-0.70%)
At close: 4:00 PM EST
€3.32
-€0.05(-0.70%)
Day’s Range― - ―
52-Week Range€1.43 - €4.74
Previous CloseN/A
Volume0.00
Average Volume (3M)1.76K
Market Cap
€1.30B
Enterprise Value€1.03B
Total Cash (Recent Filing)€296.98M
Total Debt (Recent Filing)€48.44M
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
May 07, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding411,961,600
10 Day Avg. Volume560
30 Day Avg. Volume1,762
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.85Price Target Upside106.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.43
Revenue Forecast (FY)€324.69M
Bulls Say, Bears Say
Bulls Say
Commercial MomentumGrowing demand for AMTAGVI and repeated distributor reorders of Proleukin support sustained revenue growth as more patients gain treatment access.
Pipeline And Regulatory ProgressProgress toward a regulatory filing in non-small cell lung cancer and expansion into lung, sarcoma, and endometrial indications provide clear pathways for additional product launches and broader sales.
Profitability And MarginsImproved patient use and better manufacturing raised gross margins, enhancing profitability potential as treatment volumes expand.
Bears Say
Capital Structure And DilutionPotential increases in share count could dilute earnings per share and create downward pressure on reported quarterly results.
Market SentimentPersistent investor skepticism about the tumor‑infiltrating lymphocyte approach keeps sentiment cautious and may cap valuation until confirmatory melanoma results are available.
Sales Forecast RiskAnalyst cuts to AMTAGVI sales estimates highlight downside risk to revenue projections if commercial traction slows.
Iovance Biotherapeutics News
2LB FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was €1.43 and its highest was €4.74 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is €1.30B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Feb 24, 2026. The company reported -€0.153 earnings per share for the quarter, missing the consensus estimate of -€0.149 by -€0.004.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 411,961,600 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -€0.153 in its last earnings report, missing expectations of -€0.149. Following the earnings report the stock price went up 5.465%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in DE:2LB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.85 (106.19% Upside)
€6.85 (106.19% Upside)
Blogger Sentiment
Bullish
DE:2LB Sentiment 87%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.91%
12-Months-Change
Fundamentals
Return on Equity
-54.54%
Trailing 12-Months
Asset Growth
0.30%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
2LB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial and operational momentum: strong revenue growth (Q4 $87M; FY $264M), sharp YoY growth in Amtagvi (112%), best-ever Q4 gross margin (50%), manufacturing internalization, extended cash runway to Q3 2027, regulatory progress (fast-track for lifileucel in NSCLC) and very encouraging early sarcoma signals (50% ORR in 6 evaluable patients). Offsetting these positives are outstanding execution risks — limited 2026 guidance at the time of the call, a cash runway that will require continued improvement or financing before Q3 2027, small sample size for the sarcoma data, ongoing enrollment and regulatory timing risk for registrational programs, and some dependence on distributor ordering dynamics. Overall, the highlights materially outweigh the lowlights, but continued execution on enrollment, approvals, margin improvements and cash management will be critical.View all DE:2LB earnings summaries2LB Stock 12 Month Forecast
Average Price Target
€6.85
▲(106.19% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---